Outcomes of Ranibizumab vs Aflibercept for macular oedema in
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
A Study was conducted to compare the efficacy of ranibizumab (0.5 mg) with aflibercept (2 mg) in the treatment of cystoid macular oedema due to branch retinal vein occlusion (BRVO) over 12 months that showed similar results.

A multicentre, international, database observational study recruited 322 eyes initiating therapy in real-world practice over 5 years. The main outcome measure was mean change in EDTRS letter scores of visual acuity (VA). Secondary outcomes included anatomic outcomes, percentage of eyes with VA more than 6/12 (70 letters), number of injections and visits, time to first inactivity, switching or non-completion.

--Generalised mixed effect models demonstrated that mean adjusted 12-month VA changes for ranibizumab and aflibercept were similar (+10.8 vs +10.9) letters, respectively.

--The mean adjusted change in central subfield thickness (CST) was greater for aflibercept than ranibizumab (-170 micro m vs -147 micro m, respectively).

--The overall median (Q1, Q3) of 7 injections and 9 visits was similar between treatment groups.

--First grading of inactivity occurred sooner with aflibercept. Switching was more common from ranibizumab (37 eyes) than from aflibercept (17 eyes).

Finally, despite a greater impact of aflibercept on CST and time to first grading of inactivity, visual results at 12 months in this direct comparison of ranibizumab and aflibercept for BRVO in real-world practice were generally good and comparable for the two medications.

Source: https://bjo.bmj.com/content/early/2021/03/11/bjophthalmol-2020-318491?rss=1